Satellos Bioscience (TSE:MSCL) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Satellos Bioscience successfully closed a $40 million public offering, issuing over 63 million equity securities, to fund its Phase 2 clinical program for SAT-3247. The offering was led by Bloom Burton Securities Inc. and participated by several agents. The funds will support clinical development and general corporate needs.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue